Medpace Holdings, Inc. $MEDP Shares Bought by Victory Capital Management Inc.

Key Points

• Victory Capital Management increased its stake in Medpace (NASDAQ:MEDP) by 32.9% in Q3, buying 7,565 shares to hold 30,539 shares worth about $15.7 million, and institutional/hedge funds now own roughly 77.98% of the company.
• Analysts are mixed but cautious: the consensus rating is Hold with a $486.67 target, though recent activity includes upgrades (Barclays to equal weight) and Royal Bank of Canada initiating coverage with an Outperform rating.
• Medpace reported strong quarterly results—EPS of $4.67 (vs. $4.18 est.) and revenue of $708.45M, up 32% YoY—and set FY2026 guidance of 16.680–17.500 EPS.

Victory Capital Management Inc. raised its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 32.9% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 30,539 shares of the company's stock after purchasing an additional 7,565 shares during the quarter. Victory Capital Management Inc. owned 0.11% of Medpace worth $15,702,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of MEDP. Focus Partners Advisor Solutions LLC boosted its position in Medpace by 229.7% in the third quarter. Focus Partners Advisor Solutions LLC now owns 4,487 shares of the company's stock valued at $2,307,000 after buying an additional 3,126 shares during the last quarter. Fisher Asset Management LLC increased its holdings in Medpace by 9.9% in the 3rd quarter. Fisher Asset Management LLC now owns 137,746 shares of the company's stock worth $70,824,000 after buying an additional 12,399 shares during the period. Journey Strategic Wealth LLC raised its position in Medpace by 21.8% during the 3rd quarter. Journey Strategic Wealth LLC now owns 884 shares of the company's stock worth $455,000 after buying an additional 158 shares during the last quarter. Aprio Wealth Management LLC acquired a new stake in Medpace during the 3rd quarter valued at approximately $317,000. Finally, American Century Companies Inc. lifted its stake in Medpace by 131.0% during the 3rd quarter. American Century Companies Inc. now owns 29,370 shares of the company's stock valued at $15,101,000 after acquiring an additional 16,653 shares during the period. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts have recently weighed in on MEDP shares. Barclays upgraded shares of Medpace from an "underweight" rating to an "equal weight" rating and set a $500.00 price objective on the stock in a research note on Friday, March 6th. TD Cowen raised shares of Medpace from a "sell" rating to a "hold" rating and lowered their price target for the company from $462.00 to $419.00 in a report on Wednesday, February 18th. Royal Bank Of Canada started coverage on Medpace in a research note on Tuesday, March 3rd. They set an "outperform" rating and a $522.00 price objective for the company. Mizuho set a $582.00 price objective on Medpace in a research note on Wednesday, February 11th. Finally, Leerink Partners decreased their price objective on Medpace from $575.00 to $485.00 and set a "market perform" rating for the company in a report on Wednesday, February 11th. Five analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $486.67.

Medpace Stock Performance

Shares of NASDAQ MEDP opened at $466.79 on Wednesday. The company has a market capitalization of $13.25 billion, a PE ratio of 30.51, a price-to-earnings-growth ratio of 2.29 and a beta of 1.44. The company's fifty day moving average price is $530.07 and its 200 day moving average price is $539.67. Medpace Holdings, Inc. has a 1 year low of $250.05 and a 1 year high of $628.92.

Medpace (NASDAQ:MEDP - Get Free Report) last released its quarterly earnings data on Monday, February 9th. The company reported $4.67 earnings per share for the quarter, beating analysts' consensus estimates of $4.18 by $0.49. Medpace had a net margin of 17.83% and a return on equity of 118.82%. The company had revenue of $708.45 million during the quarter, compared to analysts' expectations of $689.53 million. During the same quarter in the previous year, the company earned $3.67 earnings per share. The firm's revenue for the quarter was up 32.0% on a year-over-year basis. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, equities analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

About Medpace

Medpace Holdings, Inc NASDAQ: MEDP is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.